RxDoctor Payments Data

Julie Foreman, MD

Glaucoma Specialist · Lafayette, LANPI 1447475652

Payments from drug & device makers

$24,843in general payments, 2019–2025

Across 522 payments — averaging $47.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ivantis, Inc$9K
  • Alcon Research LLC$6K
  • AbbVie$2K
  • Alcon$2K
  • Sun Pharmaceutical Industries Inc.$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$574
  • plus $3K from 24 others

What the payments were for

  • Consulting fees$5005%
  • Food & beverage$10,10193%
  • Education$2072%
  • Gifts$190%
  • Entertainment$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$829,425
Medicare patients
1,458
Services billed
7,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj58$2,199,072
LumiganBimatoprost571$248,643
RestasisCyclosporine186$171,431
RhopressaNetarsudil Mesylate243$103,329
CombiganBrimonidine Tartrate/Timolol205$77,372
XiidraLifitegrast71$60,439
Cyclosporine107$48,629
Travoprost276$40,311
Brimonidine Tartrate1,460$38,643
VyzultaLatanoprostene Bunod107$37,440
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,914$30,424
SimbrinzaBrinzolamide/Brimonidine Tart121$27,106
MieboPerfluorohexyloctane/Pf32$26,035
Prednisolone Acetate561$25,915
Latanoprost2,156$20,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$163$2,199,07258 claims
AbbVieLumigan, Restasis, Combigan, Alphagan P$2,194$514,955997 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$339$123,914210 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$135$113,911272 claims
AlconSimbrinza$2,127$27,106121 claims
Harrow Eye, LLCVevye$266$20,62130 claims
Oyster Point Pharma, Inc.Tyrvaya$184$14,92622 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$574$3,37916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Lafayette

Where these figures come from

Is this you, or does something look wrong? →